Introduction:
Rozanolixizumab and efgartigimod are neonatal fragment crystallizable receptor blockers, approved for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG), with rozanolixizumab also approved for anti-muscle-specific tyrosine kinase antibody-positive gMG. Data are limited on patients switching from efgartigimod to rozanolixizumab. Here, we describe the demographics, clinical characteristics and treatment patterns of rozanolixizumab, and healthcare resource utilization (HCRU) among patients with gMG who received rozanolixizumab after prior treatment with efgartigimod.
Methods:
This retrospective, non-interventional study analyzed de-identified claims data from Komodo Healthcare Map® (July 2022 to June 2025) from adult patients with myasthenia gravis (MG) who started rozanolixizumab after prior efgartigimod. Patients had continuous plan coverage for 12 months before and after the index date (first rozanolixizumab treatment) and received ≥1 efgartigimod treatment ≤12 months before the index. Baseline patient profiles, treatment utilization and HCRU at baseline (12 months before the index) and follow-up (12 months after the index) were examined.
Results:
Patients (N=26) had a mean (standard deviation [SD]) age of 61.0 (16.9) years; 15/26 (57.7%) were female. The most common comorbidities were hypertension (61.5%), infections (57.7%) and dyslipidemia (53.8%). Patients initiated a mean (SD) of 3.5 (1.9) cycles during efgartigimod baseline and 2.3 (1.3) cycles during rozanolixizumab follow-up. 19.2% of patients tapered their oral corticosteroid (OCS) dose by ≥5 mg, including 7.7% who achieved complete discontinuation during follow-up. Average daily OCS dose remained stable (<5 mg change) from baseline to follow-up for 73.1% of patients. Measurements of HCRU (based on frequency and HCRU events/patient) decreased from baseline to follow-up, with consistent reductions in number of events including patients experiencing ≥1 hospitalization (50.0% vs 23.1%) and ≥1 MG exacerbation (69.2% vs 38.5%).
Conclusion:
This analysis of US patient claims data showed reductions in corticosteroid use and HCRU in patients with gMG who switched from efgartigimod to rozanolixizumab treatment.